Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on NeuroPace and keeping the price target at $18.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yi Chen has given his Buy rating due to a combination of factors that highlight NeuroPace’s strong financial performance and strategic initiatives. The company reported impressive third-quarter results for 2025, with a significant year-over-year revenue increase of 29.9%, surpassing expectations. Additionally, the net loss was considerably lower than anticipated, indicating improved financial management. The growth in revenue from the responsive neurostimulation system and the expansion of Project CARE have contributed positively to the company’s performance.
Furthermore, NeuroPace’s strategic decisions, such as the termination of the DIXI distribution agreement, allow the company to focus on its core RNS business, which is projected to grow by 20% in 2026. The company’s strong cash position and the potential for reaching cash flow breakeven by 2027 further support the Buy rating. The anticipated approval of the NAUTILUS study and the expansion into new indications are expected to drive future growth, reinforcing the positive outlook for NeuroPace.
Chen covers the Healthcare sector, focusing on stocks such as RegenXBio, VolitionRX, and Alpha Tau Medical Ltd. According to TipRanks, Chen has an average return of -4.3% and a 41.32% success rate on recommended stocks.
In another report released yesterday, Lake Street also reiterated a Buy rating on the stock with a $20.00 price target.